Dermatology Summit (Jan 6)

Going Green in 2019

Register Now
Making a DIFference in Dermatology

The mission of the Dermatology Innovation Forum is to build a community of dermatologists and their colleagues who are excited about developing ideas into products which can substantially improve skin health.

Held in association with the American Academy of Dermatology annual meeting, the forum focuses on educating participants about inspiring innovations that can provide a basis for the generation of important dermatology products and services. By including physicians, researchers, inventors, investors, strategic corporate partners, service providers, government regulators, patient advocates, and other stakeholders, the Forum also provides a unique networking venue for its attendees to communicate with, learn from, and collaborate with each other.

 

Speakers

Adewole (Ade) Adamson is a board-certified dermatologist and assistant professor in the Department of Internal Medicine at Dell Medical School at The University of Texas at Austin. His primary clinical interest is in caring for patients at high risk for melanoma of the skin, such as those with many moles (particularly atypical moles), or a personal and/or family history of melanoma.

His research involves understanding patterns of health care utilization including overuse and underuse in dermatology. He is interested in how effectively and efficiently the health care system delivers care to patients with skin cancer, the most common type of cancer in the United States. He is also passionate about health care disparities, access to specialty health care, and health care costs. He speaks nationally about health care quality, value, and the application of evidence-based medicine within dermatology.

Rox Anderson, M.D., FAAD, is Professor in Dermatology, Director of the Wellman Center for Photomedicine, and Professor of Health Sciences and Technology at MIT. Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in dermatology. These include selective photothermolysis for birthmarks, microvascular and pigmented lesions, tattoo and permanent hair removal. He also contributed to laser lithotripsy, laser angioplasty, photodynamic therapy, infrared confocal microscopy. Dr. Anderson has contributed to basic knowledge of human photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions.

Dr. Anderson graduated from MIT, received his M.D. degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology, and completed his residency in dermatology and research fellowships at Harvard.

Dr. Anderson is a past trustee of Advancing Innovation in Dermatology, having helped co-found the organization.

Douglas C. Canfield is the founder and President of Canfield Scientific, Inc., the world's leading provider of optical imaging and specialized clinical imaging and analysis solutions for dermatologists and plastic surgeons.

Canfield Scientific specializes in photographic documentation to help demonstrate drug efficacy in clinical drug trials worldwide. Canfield has pioneered the use of specialized devices in medical photography and has developed a wide range of innovative solutions for research and practice. Canfield's patented technology includes multi-spectral and multi-modal 2D and 3D image capture systems, digital asset management, aesthetic simulation, and applications for detection, measurement and analysis for various skin conditions. These technologies have contributed to the development of numerous treatments and procedures and has significantly advanced the use of optical imaging in both clinical research and practice.

Doug received his degree in Business Administration from Rutgers University.

Angela M. Christiano, PhD, is the Richard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics and Development at Columbia University Medical Center. She is also the Director of Basic Science Research in the Department of Dermatology at CUMC. For the past 20 years, Dr. Christiano's research has focused on understanding the molecular processes that lead to inherited skin and hair disorders in humans. Her research career began with the discovery of genetic mutations associated with epidermolysis bullosa, a skin disease that causes severe blistering. Dr. Christiano's recent work has focused on the investigation of the underlying genetic causes of and identification of potential therapies for alopecia areata, an autoimmune form of hair loss. She has published more than 300 papers in peer-reviewed journals and has trained more than 50 postdoctoral researchers and clinical fellows at Columbia University through the Program in Genetics & Development, the Institute of Human Nutrition, the Integrated Program in Cellular, Molecular and Biomedical Studies in the Graduate School of Arts & Sciences, the Clinical and Translational Science Award Program, and the Stem Cell Training Program.

Dr. Christiano has received numerous awards, including the New York City Mayor's Award for Excellence in Science and Technology – Young Investigator's Award, Columbia University's Harold and Golden Lamport Research Award for Excellence in Clinical Sciences, the CERIES Research Award, the North American Hair Research Society's award for Outstanding Paper of the Year, the Montagna Award from the Society for Investigative Dermatology, and the Ebling Award from the European Hair Research Society. Dr. Christiano is a prolific inventor and serial entrepreneur, having filed numerous patents on her discoveries, and successfully moved technologies from the academic setting into the commercial sector. She has co-founded several companies in the dermatology space, including Skinetics Bioscience (RNAi-based dermatology therapeutics, acquired by Sirna Therapeutics, which was acquired by Merck & Co. in 2007), Vixen Pharmaceuticals (JAK inhibitors for treatment of hair disorders, acquired by Aclaris Therapeutics in 2016), and Rapunzel Bioscience, focused on regenerative therapies and stem cell approaches for skin and hair disorders.

Dr. Christiano was past President of the Society for Investigative Dermatology (2017), and previously served as Deputy Editor of the Journal of Investigative Dermatology. She earned her MS and PhD degrees in Microbiology and Molecular Genetics from Rutgers University.

Dr. Lilit Garibyan is an Assistant Professor at Harvard Medical School and a physician scientist at the Wellman Center for Photomedicine working in Dr. Rox Anderson's laboratory. Her work focuses on innovative biomedical translational research aimed at identifying novel treatments for dermatologic diseases and beyond. She co-invented and developed a novel platform technology that uses injectable coolant for selective targeting of lipid rich tissue. Dr. Garibyan has co-developed and led an initiative at Massachusetts General Hospital called the “Magic Wand” to increase the engagement of clinical faculty in problem driven innovation.

Dr. Garibyan received her BS summa cum laude from University of California Los Angeles, her MD from Harvard Medical School and her PhD from Harvard University in Experimental Pathology/Immunology.

Chris Griffiths qualified in Medicine from St Thomas' Hospital Medical School, London. He trained in Dermatology at St Mary's Hospital, London, and at the University of Michigan, USA. He was appointed to the Foundation Chair in Dermatology at the University of Manchester in 1994 and is an honorary consultant dermatologist at Salford Royal NHS Foundation Trust. He founded the Manchester Dermatopharmacology Unit and Manchester Psoriasis Service in 1994. At the University of Manchester he has held several senior posts including Faculty Research Dean and Director of the Manchester Academic Health Science Centre. He currently leads for precision medicine in the UK Government’s Manchester Devolution initiative. Chris received a lifetime achievement award from the American Skin Association in 2009. In 2015 he received the Sir Archibald Gray Medal for outstanding service to British Dermatology and the Society of Cosmetic Scientists Medal. He is a National Institute for Health Research (NIHR) Senior Investigator, Fellow of the Academy of Medical Sciences and elected Member of Academia Europaea. Chris was appointed an Officer of the Order of the British Empire (OBE), for services to dermatology, in the 2018 New Year's Honours.

Professor Griffiths is a past-President of the British Association of Dermatologists, European Dermatology Forum, British Society for Investigative Dermatology and International Psoriasis Council. He is an Executive Board member of the International League of Dermatological Societies and Secretary/Treasurer of the European Society for Dermatological Research. Chris is Director of the MRC funded stratified medicine consortium on psoriasis (Psoriasis Stratification to Optimise Relevant Therapy; PSORT) and Chief Investigator of the British Association of Dermatologists Biologic Interventions Register (BADBIR). He has 621 Pubmed cited articles (h-index 92), and is Editor-in-Chief of Rook’s Textbook of Dermatology. Chris has long-standing research interests in all aspects of psoriasis and skin ageing

Dr. Brian Kim is Assistant Professor of Dermatology, Anesthesiology, Pathology and Immunology, and Co-Director of the Center for the Study of Itch at Washington University School of Medicine in St. Louis. His laboratory focuses on innate immune mechanisms that underlie skin inflammation and the sensation of itch. Specifically, the Kim Lab identified previously unrecognized contributions of group 2 innate lymphoid cells (ILC2s) and basophils to the pathogenesis of atopic dermatitis (AD) in both mice and humans. These cells have emerged as critical sources of the type 2 cytokines IL-4, IL-5, and IL-13, which are now among the most important targets for biologic therapy in AD and other allergic disorders. More recently, the Kim Lab was the first to identify functionality of IL-4 receptor alpha (IL-4Rα) and Janus kinases (JAKs) in sensory neurons as master regulators of chronic itch in AD and other disorders. These studies have immediate clinical implications as type 2 cytokine and JAK blockade have emerged as some of the most efficacious therapeutics in AD. His research on the immune regulation of AD and itch has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, and the American Society for Clinical Investigation.

Justin M. Ko, MD MBA, joined Stanford Medicine in 2012 and serves as Director and Chief of Medical Dermatology for Stanford Health Care (SHC) as well as spearheading the dermatology department's efforts around telehealth and quality/safety/performance improvement. He is active in a number of leadership roles within the organization including co-chairing the Clinic Advisory Council, a forum of medical and executive leaders of Stanford Health Care's Ambulatory clinics, and as a Medical Director of Patient Experience.

His passion for melanoma, early cancer detection, and improving care delivery drives his efforts and research around leveraging advances in machine learning and artifical intelligence to increase the breadth of populations that can be reached. Further, he developed and runs a virtual teledermatology care delivery program at SHC, providing virtual visits for patients and remote consultations for providers within the network. He is currently working on exploring collaborations and interventions that layer advances in deep learning on remote care capabilities to enhance access, quality and value of dermatologic care.

His passion for melanoma, early cancer detection, and improving care delivery drives his efforts and research around leveraging advances in machine learning and artifical intelligence to increase the breadth of populations that can be reached. Further, he developed and runs a virtual teledermatology care delivery program at SHC, providing virtual visits for patients and remote consultations for providers within the network. He is currently working on exploring collaborations and interventions that layer advances in deep learning on remote care capabilities to enhance access, quality and value of dermatologic care.

Dr. Sailesh Konda is an Assistant Clinical Professor of Dermatology at the University of Florida Health System where he serves as Medical Director, Co-Director of Mohs Surgery and Surgical Dermatology, and Director of Cosmetic Dermatology and Laser Surgery.

He completed his undergraduate and medical education at the George Washington University as part of a competitive seven-year BS/MD program. He went on to complete an internship in internal medicine at Boston University/Boston Medical Center and worked as a research associate at the University of California, San Francisco. After completing his dermatology residency at Howard University Hospital, he received additional fellowship training in Mohs surgery/procedural dermatology at Loma Linda University Medical Center. During his fellowship, he also worked at Riverside County Regional Medical Center and served as a Volunteer Assistant Clinical Professor at the University of California, Riverside.

He has collaborated and co-authored numerous research publications and book chapters with colleagues from around the country. He has a special interest in the evolving role of private equity within dermatology. Dr. Konda is a fellow of the American Academy of Dermatology, an associate member of the American College of Mohs Surgery, and a fellow of the American Society of Dermatologic Surgery.

Markham C. Luke is a Supervisory Medical Officer and Director of the Division of Therapeutic Performance (DTP) in the Office of Research and Standards, Office of Generic Drugs at FDA. DTP is responsible for facilitating pre-application development of generic drugs by conducting and promoting regulatory science research to establish standards to ensure therapeutic equivalence of new generic drug products. Markham has an MD and a PhD in Pharmacology from Johns Hopkins University and is a dermatologist by training. Markham has research interests in dermatopharmacology, clinical pharmacology, clinical study design and endpoints assessment (including patient-reported outcomes) for medical, surgical, and aesthetic products and serves as consultant dermatologist to various parts of FDA. Markham has been at FDA since 1998 serving various roles, including as the Lead Medical Officer for dermatology drugs, Chief Medical Officer and Deputy Director for the Office of Device Evaluation in the Center for Devices and Radiologic Health, and as Acting Director for Cosmetics in the Center for Food Safety and Applied Nutrition. In each of these roles including his current one, Markham has been involved in programs and initiatives dealing with product innovation as related to Public Health for our nation.

Douglas Lowy, M.D., is the Deputy Director of the National Cancer Institute (NCI) of the National Institutes of Health (NIH) since 2010.

A cancer researcher for more than 40 years, Dr. Lowy received the National Medal of Technology and Innovation from President Obama in 2014 for his research that led to the development of the human papillomavirus (HPV) vaccine. As chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI, Lowy’s research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. His laboratory, in close collaboration with John T. Schiller, Ph.D., was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three U.S. Food and Drug Administration-approved HPV vaccines.

Dr. Lowy is a member of the National Academy of Sciences (NAS), as well as the Institute of Medicine of the NAS. For their pioneering work, Lowy and Schiller have received numerous honors in addition to the National Medal, including the Federal Employee of the Year Award in 2007 from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, and the 2017 Lasker~DeBakey Clinical Medical Research Award.

Lowy received his medical degree from New York University School of Medicine, New York City, and trained in internal medicine at Stanford University, California, and dermatology at Yale University, New Haven, Connecticut.

Raymond A. Miller is a partner and member of the Leadership Team of the Health Sciences Department of Pepper Hamilton LLP, resident in the Pittsburgh office. A registered patent attorney, Mr. Miller focuses his practice on identifying, protecting, securing and maximizing the value of clients' intellectual property. Mr. Miller is a former member of the firm's Executive Committee and was previously co-chair of the firm's Intellectual Property Department.

Mr. Miller's clients include universities, research institutes and businesses ranging from idea stage through Fortune 500 companies, as well as other organizations and individuals involved in basic research and technology transfer. He has represented Ivy League universities, research organizations, pharmaceutical companies, biotechnology companies, consumer products companies, manufacturing companies, computer software developers and R&D contractors. His practice includes both prosecution and transactional IP, including acquiring and licensing patents, trademarks, copyrights and trade secrets, as well as litigation.

Mr. Miller's practice includes an array of chemical, medical, pharmaceutical, mechanical, environmental and business method fields. While he is particularly adept at handling technologies in the life sciences, he also is proficient in areas of material sciences, metallurgy, thin-film technology, specialty chemicals, polymer chemistry, nanotechnology and cosmetics.

Dr. Piacquadio is the Founder and CEO/President of Therapeutics, Inc. He has been active in clinical research and medical product development since 1985, when he worked as the Director of Research and Development for Oncotherm, a biotechnology company in the field of hyperthermia where his responsibilities included regulatory affairs and clinical development. Since that time, he has started the clinical research program for the Division of Dermatology, University of California, San Diego. From 1989 to 1997, he served as Director of this organization, which became regarded as one of the leading academic product development groups in the United States. In 1997 he started Therapeutics, Inc as a research and development business dedicated to the field of dermatology serving the needs of the biotechnology, pharmaceutical and investment community.

Dr. Piacquadio has also actively participated in the development of a wide variety of biotechnology start-ups and medical product development programs. He has been instrumental in the pre-clinical and clinical development phase of a variety of soft tissue augmentation products including Hylaform® (Biomatrix) and was instrumental in regulatory strategy and clinical development of the first laser based hair removal technology pioneered by Thermolase among others. As a consultant for the FDA Generic Drug Group he assisted in the development of the current bioequivalency standards for topical steroids. Presently he serves in an advisory capacity for a variety of biotechnology and pharmaceutical companies.

Dr. Piacquadio received his B.S. degree in Biomedical Engineering from Rensselaer Polytechnic Institute and received his medical degree from the University of Pennsylvania. He received his graduate clinical training at Brown University as an intern in Internal Medicine and his Dermatology training at University of California, San Diego.

Adam Raff, M.D., Ph.D. is currently a dermatology physician-scientist at the Massachusetts General Hospital (MGH). He works on developing point-of-care diagnostics for infectious and inflammatory diseases of the skin. He received his undergraduate degree in biology and biochemistry from Georgetown University summa cum laude with Phi Beta Kappa honors. He received his MD with Alpha Omega Alpha honors and his PhD in Systems Biology and Disease under W. Martin Kast PhD at the University of Southern California. Dr. Raff completed his dermatology residency at Harvard and his post-doctoral fellowship as an NIH-funded T32 fellow under R. Rox Anderson MD at MGH. Dr. Raff was a founding member of the Education Committee for Advancing Innovation in Dermatology (AID). He previously served as AID Education Committee chair, and currently serves as Virtual Magic Wand Co-Chair and Director of the Hacking Dermatology Initiative.

Gabriel Sanchez is the CEO and co-founder of Enspectra Health, a Stanford University spin out currently in residence at the Fogarty Institute for Innovation in Mountain View CA. Enspectra has created a portable microscope that images real-time cellular anatomy in living tissue without cuts or stains. This technology introduces a new field of medical imaging, non-invasive histopathology, and the feature rich images are ideal for pairing with emerging AI tools in machine vision. Enspectra is targeting this technology first for early detection of skin cancer which is the most common of all malignancies. Gabriel received his B.S. in mechanical engineering from MIT, and an M.S. and Ph.D. in mechanical engineering from Stanford University. Following his Ph.D., Gabriel served as an instructor in the Stanford Bioengineering department where he developed and taught curriculum for the undergraduate medical device design courses.

Eric Schweiger, MD, FAAD, is the founder and C.E.O. of Schweiger Dermatology Group (SDG), a leading cosmetic and medical dermatology practice in the Tri-State area.

Dr. Schweiger founded SDG in 2010 with one office and a single employee and has since grown to over 45 offices with over 700 employees and 140 healthcare providers. Over the past four years, Dr. Schweiger has raised over $100 Million in private equity capital which has been deployed to help facilitate SDG’s growth via a combination of de novo offices and strategic acquisitions.

The mission of SDG is to deliver the Ultimate Patient Experience and make high-quality dermatology services easily accessible to people in the Northeast. Wait times to see a dermatologist are historically long, and Dr. Schweiger's goal is to increase access to dermatologic care by opening new practices and revitalize existing practices throughout the area and by offering same-day appointments and extended hours. Today, SDG provides dermatology care to over 500,000 patients annually.

Dr. Schweiger received his B.A. from the University of Michigan and his medical degree from the Albert Einstein College of Medicine. He completed his post-doctoral training at New York University and the University of Kansas Medical Center. Dr. Schweiger also serves on the dermatology faculty at Mount Sinai Medical School in New York City.

Dr. Schweiger is honored to have been a 2018 EY Entrepreneur of the Year Finalist and Schweiger Dermatology Group was named to the in both 2017 and 2018 to the Inc. 5000 list of fastest growing private companies in America as well as the Crain’s New York Fast 50, which honors the fastest growing companies in New York.

Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline's Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 24 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.

David T. Woodley, M.D. completed his undergraduate degree in English Literature at Washington University in St. Louis and his medical school education at the University of Missouri in Columbia, Missouri. He completed his dermatology residency training at the University of North Carolina in Chapel Hill, North Carolina. He then completed a Dermatology Research Fellowship in the laboratory of Dr. Michel Prunieras at the Rothschild Foundation and University of Paris in Paris, France. He served as an Expert Investigator at the National Institutes of Health for three years and then returned to Chapel Hill as an Assistant Professor of Dermatology. He left Chapel Hill in 1989 to be Professor and Associate Chair of the Department of Dermatology at Stanford University. In 1992, he was appointed the Walter Hamlin Professor and Chair of Dermatology at Northwestern University. In 1999, he joined the medical faculty at the Keck School of Medicine of the University of Southern California (USC) and in 2004, he assumed his current position as the Founding Chair of the USC Department of Dermatology.

Dr. Woodley is the author of over 200 original articles and is a clinician-investigator with continuous NIH funding since 1982. He is the Co-Editor of a book entitled The Biology of Skin with Dr. Ruth Freinkel and serves as an Associate Editor of The Journal of the American Academy of Dermatology, The Archives of Dermatology, Clinical and Experimental Dermatology and Dermatology. Dr. Woodley’s scientific interests include type VII collagen, keratinocyte motility, wound healing, keratinocyte-derived collagenases, autoimmune bullous diseases and hereditary dystrophic epidermolysis bullosa. He has served on numerous American Academy of Dermatology committees, the Board of Directors of the Society for Investigative Dermatology, the Board of Directors of the California Dermatology Society, and the Board of Directors of the LA Metropolitan Dermatology Society. He is the current past President of the LA Metropolitan Dermatology Society and the President-Elect of the California Dermatology Society. He has been elected to the American Society of Clinical Investigation (ASCI), the American Dermatological Association (ADA) and the Association of American Physicians (AAP). Four NIH RO1 grants, one Challenge Grant and one VA Merit Review Grant support the USC Laboratory for Investigative Dermatology.

 

Program

8:00AM

Registration and Networking Café

8:50AM

Welcome

  • William Ju, MD, FAAD
  • President & Founding Trustee , Advancing Innovation in Dermatology, Inc.
9:00AM

Session 1 - MAGIC WAND℠

Co-Chair
  • Rox Anderson, MD, FAAD
  • Professor , Harvard Medical School ; Director , Wellman Center for Photomedicine at Massachusetts General Hospital
Co-Chair
  • Lilit Garibyan, MD, PhD, FAAD
  • Assistant Professor , Harvard Medical School
  • Physician-Scientist , Wellman Center for Photomedicine at Massachusetts General Hospital
10:00AM

Panel: What's the Impact of Technology on Dermatologists?

Chair
  • Justin M. Ko, MD, MBA
  • Director & Chief of Medical Dermatology , Stanford Health Care
  • Ade Adamson, MD, MPP
  • Assistant Professor, Department of Medicine at Dell Medical School , University of Texas at Austin
  • Gabriel Sanchez, PhD
  • CEO & Co-Founder of Enspectra Health , Fogarty Institute for Innovation
11:00AM

Networking Break

11:30AM

Hacking Dermatology

Chair
  • Adam Raff, MD, PhD, FAAD
  • Instructor , Harvard Medical School ; Physician-Scientist , Wellman Center for Photomedicine at Massachusetts General Hospital
12:10PM

Leadership Sponsor Panel

  • Raymond A. Miller, JD
  • Partner , Pepper Hamilton LLP
  • Michael L. Sierra, PhD
  • Vice President , LEO Science & Tech Hub
12:40PM

Lunch

1:30PM

Session 2 - What's the Future

Co-Chair
  • Angela Christiano, PhD, FACMG
  • Vice-Chair of Research, Departments of Dermatology and Genetics & Development , Columbia University
Co-Chair
  • Chris Griffiths, OBE, MD, FRCP
  • Director of the Manchester Centre for Dermatology Research and Head of the Dermatology Theme of the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre , University of Manchester
Presenters
  • Brian S. Kim, MD, MTR
  • Assistant Professor of Dermatology, Anesthesiology, and Pathology and Immunology; Co-Director, Center for the Study of Itch , Washington University School of Medicine
  • David T. Woodley, MD
  • Professor and Emeritus Founding Chair, USC Department of Dermatology, The Keck School of Medicine , University of Southern California
2:30PM

Featured Speaker

  • Douglas Lowy, MD
  • Deputy Director, National Cancer Institute , National Institutes of Health
2:55PM

Networking Break

3:25PM

Session 3 - Innovations in Clinical Research and Product Development

Chair
  • Daniel Piacquadio, MD, FAAD
  • Founder, Chief Executive Officer and President , Therapeutics, Inc.
Presenters
  • Douglas C. Canfield
  • Founder and President , Canfield Scientific, Inc.
  • Alice Gottlieb, MD, PhD, FAAD
  • Department of Dermatology , Icahn School of Medicine at Mt. Sinai
  • Markham C. Luke, MD, PhD, FAAD
  • Medical Officer & Director , FDA
4:25PM

Panel: Point/Counterpoint - Private Equity and Dermatology Practices

Moderator
  • Seth Orlow, MD, PhD, FAAD
  • Senior Advisor , Pharus Advisors, LLC
  • Professor & Chair of Dermatology , NYU School of Medicine
Panelists
  • Sailesh Konda, MD, FAAD
  • Assistant Clinical Professor of Dermatology , University of Florida College of Medicine
  • Eric Schweiger, MD, FAAD
  • Founder & Chief Executive Officer , Schweiger Dermatology Group
4:55PM

Summary / Close

 

People

Conference Board of Directors

Frederick C. Beddingfield III is founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. He started Sienna in 2016 and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he led the development of global leading brands in medical dermatology and aesthetics including Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. He has led multiple successful FDA advisor committees.

Since completing his training, Frederick has always maintained a clinical and teaching practice at UCLA where he is an Associate Clinical Professor. He is a board-certified dermatologist and emergency medicine physician and a fellowship trained dermatologic surgeon. Frederick completed his medical degree at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder.

Albert Cha, MD, PhD. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), BioHaven Pharmaceuticals (NYSE: BHVN), KalVista Pharmaceuticals (NASDAQ: KALV), Menlo Therapeutics (NASDAQ: MNLO).

He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.

John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $2B+ in assets under management.

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.

Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of EdWiser, Inc. (now known as Zoomi, Inc.), is currently a member of the board of directors for Brickell Biotech, Inc., and serves on the Advisory Council for the Keller Center for Innovation Engineering Education at Princeton University.

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Dr. Neal Walker co-founded Aclaris Therapeutics and has served as President and Chief Executive Officer and a member of the board of directors since inception July 2012. He is a board certified dermatologist and serial entrepreneur with over 19 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson, Inc.

DDr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in August 2012. Prior to Aclaris, he co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the Board of Directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies.

In 2016 Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award, and also the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology, received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine, and a B.A. degree in Biology from Lehigh University.

 

Sponsors

For Sponsorship Opportunities, please contact Rhonda Ware at rware@caravelgroupinc.com .
 

Networking

New! Conference App in 2019

This year the Dermatology Summit will be utilizing a conference app for the meeting material and networking appointments, available on both Apple and Android devices for all registered attendees.

This app will replace our conference networking software from recent years. Upon logging into the app, you will be able to network with other attendees and set up meetings in our 1:1 conference networking space.

Our app will launch in mid-January, and you will receive an email at that time with download instructions.

 

Contact

Event Details

Erin Conner, CMP
Caravel Group
econner@caravelgroupinc.com

Sponsorship Opportunities

Rhonda Ware
Caravel Group
rware@caravelgroupinc.com

Venue Details

TBD

 

Frequently Asked Questions

What is the agenda for the conference?

The current program agenda can be found here.

What is the cost of registration?

  • If registered by November 30, 2018 - $145 Academician / $395 Industry
  • Registration after November 30, 2018 - $245 Academician / $595 Industry

What is included in the registration fees?

Conference registration includes:

  • Networking Café
  • Networking Lunch
  • Networking Breaks
  • All Conference Sessions
  • Access to Conference App for Networking Opportunities

How do I become a Sponsor?

If you are interested in a sponsorship opportunity, please contact Rhonda Ware at rware@caravelgroupinc.com, for the sponsorship overview and level pricing.

Networking

Our app will launch in mid-January, and you will receive an email at that time with download instructions to network with other conference attendees and set up 1:1 meetings in our dedicated networking space.

Where can I make hotel reservations?

If you will be attending the Annual AAD conference, you will need to visit the website at www.aad.org to request hotel accommodations. Housing requests open on Wednesday, November 14th at 12pm (CT). If you are not attending the Annual AAD Conference, a list of local hotels will be available on www.aad.org after November 14th.

The Dermatology Summit does not have contracted rates with these hotels.

What is the dress code?

Attire is business casual. Feel free to be comfortable in slacks, polo shirts, blazers, blouses and most importantly, comfortable shoes. We do recommend you dress in layers as temperatures in meeting rooms can vary.

I am a Sponsor. How do I redeem my contracted complimentary registration(s)?

After your sponsorship has been processed, you will receive an email with a unique code and instructions to register online. We encourage all complimentary and discounted registrations to be completed by January 28, 2019. If you have not yet received the email, please contact us at rware@caravelgroupinc.com.

Cancellation Policy

Requests for registration fee cancellations for the conference must be received on or before January 28, 2019 by 3pm Eastern Time. At the discretion of the conference organizers, a refund via the method of original payment, minus a $125 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on January 28, 2019. Written notice of your cancellation should be sent to econner@caravelgroupinc.com with a copy to info@advancing-derm.org.

Force Majeure

No damages or refunds shall be due for a failure of performance by the occurrence of any contingency beyond the reasonable control of AID or Caravel Group. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, failure or delay in transportation, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, interruptions or failure of the Internet or third-party network connections, or acts beyond the reasonable control of the responsible parties making the Event impossible to hold.

Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.